Brief: Sandoz Confirms European Commission Approval For Biosimilars Bysumlog And Dazparda
15/05/2026 12:03
May 15 (Reuters) - SANDOZ GROUP AG SDZ.S: CONFIRMS EUROPEAN COMMISSION APPROVAL FOR BIOSIMILARS BYSUMLOG® (INSULIN LISPRO) AND DAZPARDA® (INSULIN ASPART), STRENGTHENING POSITION IN DIABETES Source text: ID:nEQ6B2Kc9a Further company coverage: SDZ.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sandoz AG
See all newsPfizer dismissed from US states' drug price-fixing lawsuit (updated)
Pfizer dismissed from US states' drug price-fixing lawsuit
Factbox: Major investment pledges at Choose France summit
Press Digest: Financial Times - June 1
Media: Sandoz warns cheap Chinese imports threaten Europe’s antibiotic supply- FT